Avoid common mistakes on your manuscript.
Correction to: Journal of Neuro-Oncology https://doi.org/10.1007/s11060-019-03279-9
The following discrepancies and errors were found in the original publication:
As correctly specified in Table 1, the male PCNSL patients treated with HD-MTX made up 46% of that group (not 54% as specified in the Abstract and the text of the Results section).
As correctly specified in the Results section (Table 2 and text), the average first detected WMC score was 0.8 (± 0.9) (mean, ± SD) in the HD-MTX group; not 1.5 (± 0.6) as specified in the Abstract. Also, the term ‘non-zero’ in the Abstract and in the text of the Results section should not have been used here.
As correctly specified in Table 2, the p-value for the Overall WMC score is 0.0048; not 0.04 as specified for the average WMC score in the text in the Results section.
In the first column of Table 2, the word 'years' in the bottom entry should read 'months'.
In the Results section, the second sentence in the second paragraph should read as follows: "Median time to detect WMC was shorter in the HD-MTX-R group compared to the HD-MTX group".
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Estephan, F., Ye, X., Dzaye, O. et al. Correction to: White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab. J Neurooncol 145, 467 (2019). https://doi.org/10.1007/s11060-019-03346-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-019-03346-1